Table 2 Baseline characteristics of the patients with bulky parotid cancer (equal to or greater than 4 cm in the longest diameter)
Characteristics (N = 60) | No.(%) |
|---|---|
Age (median, with interquartile range, years) | 58.0 [47.0–71.0] |
Sex (Male:Female) | 40:20 (66.7:33.3) |
Tumor size (longest diameter)a (median with interquartile range, cm) | 4.3 [4.0–6.0] |
Facial nerve palsy at diagnosis | 16 (26.7) |
TNM stageb | |
T3:T4 | 20:40 (33.3:66.7) |
N0:N1:N2:N3 | 28:7:24:1 (46.6:11.6:40.0:1.7) |
M0:M1 | 52:8 (86.7:13.3) |
Tumor pathology | |
Carcinoma ex pleomorphic adenoma | 11 (18.3) |
Adenocarcinoma not otherwise specified | 10 (16.7) |
Mucoepidermoid carcinoma | 10 (16.7) |
Salivary duct carcinoma | 10 (16.7) |
Adenoid cystic carcinoma | 7 (11.7) |
Acinic cell carcinoma | 3 (5.0) |
Myoepithelial carcinoma | 2 (3.3) |
Othersc | 7 (11.7) |
Tumor grade | |
High grade | 26 (43.3) |
Intermediate grade | 2 (3.3) |
Low grade | 29 (48.3) |
Unknown | 3 (5.0) |
Treatments | |
Surgery with adjuvant RT or CCRT | 47 (78.3) |
RT or CCRT (with salvage surgery) | 11 (18.3) |
Chemotherapy or no treatments | 2 (3.3) |
Survival outcomes | |
No evidence of disease | 31 (51.7) |
Alive with disease | 6 (10.0) |
Cancer-related death | 22 (36.6) |
Unrelated death | 1 (1.7) |
Follow-up period (median, range, months) | 18.2 [0.7–200.2] |